Literature DB >> 33663315

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps.

Wenli Fan1, Lin Zhang1, Xuejiang Wang2, Haiyong Jia1, Lei Zhang1.   

Abstract

In discovery of novel HDAC inhibitory with anticancer potency, pharmacophores of phenanthridine were introduced to the structure of HDAC inhibitors. Fatty and aromatic linkers were evaluated for their solubility and activity. Both enzyme inhibitory and in vitro antiproliferative (against U937 cells) screening results revealed better activities of compounds with aromatic linker than molecules with fatty linker. Compared with SAHA (IC50 values of 1.34, 0.14, 2.58, 0.67 and 18.17 µM), molecule Fb-4 exhibited 0.87, 0.09, 0.32, 0.34 and 17.37 µM of IC50 values against K562, U266, MCF-7, U937 and HEPG2 cells, respectively. As revealed by cell cycle and apoptotic analysis, induction of G2/M phase arrest and apoptosis plays an important role in the inhibition of MCF-7 cells by Fb-4. Generally, a potent HDAC inhibitor was developed in the present study which could be utilised as a lead compound for further anticancer drug design.

Entities:  

Keywords:  Histone deacetylase; anticancer; inhibitor; linker; phenanthridine

Mesh:

Substances:

Year:  2021        PMID: 33663315      PMCID: PMC7939570          DOI: 10.1080/14756366.2021.1892089

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  13 in total

1.  Genomewide studies of histone deacetylase function in yeast.

Authors:  B E Bernstein; J K Tong; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling.

Authors:  Cristiana Foglietti; Gessica Filocamo; Enrico Cundari; Emanuele De Rinaldis; Armin Lahm; Riccardo Cortese; Christian Steinkühler
Journal:  J Biol Chem       Date:  2006-04-21       Impact factor: 5.157

Review 3.  Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Authors:  Armin Rashidi; Amanda F Cashen
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

Review 4.  Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.

Authors:  Lei Zhang; Yantao Han; Qixiao Jiang; Chunbo Wang; Xuehong Chen; Xiaoguang Li; Fuming Xu; Yuqi Jiang; Qiang Wang; Wenfang Xu
Journal:  Med Res Rev       Date:  2014-04-29       Impact factor: 12.944

5.  Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.

Authors:  Fan Yun; Chunhui Cheng; Sadeeq Ullah; Jie He; Mohamed Reda Zahi; Qipeng Yuan
Journal:  Eur J Med Chem       Date:  2019-05-10       Impact factor: 6.514

Review 6.  Therapeutic potential of selective histone deacetylase 3 inhibition.

Authors:  Lihui Zhang; Yiming Chen; Qixiao Jiang; Weiguo Song; Lei Zhang
Journal:  Eur J Med Chem       Date:  2018-11-17       Impact factor: 6.514

Review 7.  Discovery and development of SAHA as an anticancer agent.

Authors:  P A Marks
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 8.  Strategies in developing promising histone deacetylase inhibitors.

Authors:  Lei Zhang; Hao Fang; Wenfang Xu
Journal:  Med Res Rev       Date:  2010-07       Impact factor: 12.944

Review 9.  Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.

Authors:  Sarah L Greig
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

10.  Synthesis and Anticancer Activity Evaluation of Novel Phenanthridine Derivatives.

Authors:  Minghui Wan; Lei Zhang; Yiming Chen; Qiang Li; Wenli Fan; Qingxia Xue; Fang Yan; Weiguo Song
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

View more
  3 in total

1.  Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.

Authors:  Lin Zhang; Yiming Chen; Fahui Li; Lihui Zhang; Jinhong Feng; Lei Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  Discovery of 2-Phenylquinoline-4-Carboxylic Acid Derivatives as Novel Histone Deacetylase Inhibitors.

Authors:  Qian Hui; Lihui Zhang; Jinhong Feng; Lei Zhang
Journal:  Front Chem       Date:  2022-07-14       Impact factor: 5.545

3.  Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors.

Authors:  Fahui Li; Lihui Zhang; Jinhong Feng; Lei Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.